1 day Ago By ABMN Staff
GeneDx Holdings Corp. ( NASDAQ:WGS – Get Free Report ) CEO Katherine Stueland sold 46,551 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $95.
62, for a total value of $4,451,206.62. Following the completion of the sale, the chief executive officer now directly owns 48,314 shares of the company’s stock, valued at $4,619,784.
68. The trade was a 49.07 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Katherine Stueland also recently made the following trade(s): GeneDx Stock Performance Shares of WGS opened at $92.20 on Monday.
The company has a market capitalization of $2.59 billion, a PE ratio of -47.04 and a beta of 1.
91. GeneDx Holdings Corp. has a 52-week low of $8.
53 and a 52-week high of $115.60. The company has a 50-day simple moving average of $87.
28 and a 200-day simple moving average of $74.48. The company has a quick ratio of 2.
27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.
Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in WGS. Charles Schwab Investment Management Inc. boosted its position in shares of GeneDx by 304.
3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after buying an additional 110,666 shares in the last quarter.
FMR LLC lifted its holdings in shares of GeneDx by 295.6% in the third quarter. FMR LLC now owns 53,825 shares of the company’s stock valued at $2,284,000 after purchasing an additional 40,219 shares in the last quarter.
Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of GeneDx in the third quarter valued at approximately $7,533,000. MetLife Investment Management LLC purchased a new position in shares of GeneDx during the 3rd quarter worth approximately $310,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of GeneDx during the 3rd quarter worth approximately $325,000.
Hedge funds and other institutional investors own 61.72% of the company’s stock. Analyst Upgrades and Downgrades A number of research firms recently weighed in on WGS.
The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th.
TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th.
Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.
Check Out Our Latest Analysis on WGS GeneDx Company Profile ( Get Free Report ) GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter ..
